Business Context and Reporting Period
Company: Spero Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2024
Event: Regulation FD Disclosure regarding an updated Investor Presentation.
Key Financial Metrics
This filing does not contain specific financial statements, revenue, profit, cash flow, margin, debt, or liquidity figures. The document serves solely to disclose the availability of an updated Investor Presentation.
Material Changes
No material financial changes or operational updates are detailed within the text of this 8-K. The only reported change is the update of the company's Investor Presentation dated January 8, 2024.
Guidance, Outlook, and Risks
Management Commentary: The Company updated its Investor Presentation for use in general corporate presentations. The presentation is available on the Company's website or in hardcopy/electronic form.
Disclaimer: The Company explicitly disclaims any obligation to update the Investor Presentation after January 8, 2024.
Legal Status: The information furnished in this Item 7.01 and the attached Investor Presentation is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that Section. It shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Verify the content of the attached Exhibit 99.1 (Investor Presentation) for specific clinical or financial data not included in this summary.
- Confirm the date of the Investor Presentation is January 8, 2024, as older versions may be superseded.
- Note that the Company has no obligation to update the presentation after the filing date.
- Review the Company's website for the electronic distribution of the presentation.